ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results • Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year • Pu rified Cortrophin ® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year • Quarterly GAAP net inco
How this was made
The 30-second read
Why it matters
The earnings beat and updated guidance provide fresh material for traders, while the acquisition premium signals confidence in long‑term growth, likely supporting the stock.
Market read
ANI's earnings beat, updated guidance, and acquisition announcement create a clear catalyst for immediate price movement.
What to watch
Capacity constraints in the specialty pharmacy network could limit revenue conversion despite strong demand.
Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year; ANI revised full-year total company revenue guidance to $1,085 million - $1,125 million and raised adjusted non-GAAP EBITDA and adjusted non-GAAP diluted EPS guidance.
Third-quarter revenue, Rare Disease revenue, GAAP net income, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS all increased year over year. Cortrophin Gel conversion was slower than expected because of specialty-pharmacy capacity constraints, and the company reduced its Cortrophin Gel revenue outlook.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Third quarter net revenuesGAAP | $290.8M | – | 27.6 % |
| Third quarter cost of sales (excluding depreciation and amortization)GAAP | 111,531 | – | – |
| Third quarter gross profitGAAP | $179.2M | – | – |
| Third quarter GAAP gross marginGAAP | 61.6 % | – | – |
| Third quarter non-GAAP gross profitnon-GAAP | $179.8M | – | – |
| Third quarter non-GAAP gross marginnon-GAAP | 61.8 % | – | – |
| Third quarter research and development expenseGAAP | 12,997 | – | 5.6% |
| Third quarter non-GAAP research and development expensenon-GAAP | $12.34M | – | 4.7% |
| Third quarter selling, general, and administrative expenseGAAP | 94,862 | – | 23.8% |
| Third quarter non-GAAP selling, general, and administrative expensenon-GAAP | $84.15M | – | 32.4% |
| Third quarter depreciation and amortizationGAAP | 19,552 | – | – |
| Third quarter contingent consideration fair value adjustmentGAAP | (538) | – | – |
| Third quarter operating incomeGAAP | 52,373 | – | – |
| Third quarter interest expense, netGAAP | (3,056) | – | – |
| Third quarter income before income tax expenseGAAP | 49,041 | – | – |
| Third quarter income tax expenseGAAP | 13,892 | – | – |
| Third quarter net incomeGAAP | $35.15M | – | – |
| Third quarter net income available to common shareholdersGAAP | $35.15M | – | – |
| Third quarter diluted income per shareGAAP | $ 1.51 | – | – |
| Third quarter adjusted non-GAAP EBITDAnon-GAAP | $83.30M | – | 39.8% |
| Third quarter adjusted non-GAAP net income available to common shareholdersnon-GAAP | $58.21M | – | – |
| Third quarter adjusted non-GAAP diluted earnings per sharenon-GAAP | $ 2.70 | – | – |
| Nine months net revenuesGAAP | $794.3M | – | – |
| Nine months operating incomeGAAP | 131,721 | – | – |
| Nine months net income available to common shareholdersGAAP | $89.35M | – | – |
| Nine months diluted income per shareGAAP | $ 3.86 | – | – |
| Nine months adjusted non-GAAP EBITDAnon-GAAP | $217.9M | – | – |
| Nine months adjusted non-GAAP diluted earnings per sharenon-GAAP | $ 6.96 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Cortrophin GelGrowth was driven primarily by increased volume, including momentum from the gout expansion and continued progress in existing specialty areas. | $138.7M | – | 36.1 % |
| ILUVIENIncreased volumes and phasing of international shipments. | $22.25M | – | 34.1 % |
| Rare Disease total net revenuesIncludes Cortrophin Gel and ILUVIEN. | $160.9M | – | 35.8 % |
| BrandsNet decrease in demand for certain products. | 9.98M | – | (6.5) % |
| Brand royalties and other revenuesIncludes $2.0 million of development-milestone revenue and royalties of approximately $9.5 million related to the Harmony Agreement. | 11.46M | – | N/M |
| Rare Disease and Brands total net revenuesGrowth reflected Cortrophin Gel, ILUVIEN, and Harmony Agreement revenue. | $182.3M | – | 41.2 % |
| Generic pharmaceutical productsStrong market demand for existing products and new product launches in 2025 and 2026. | 104.5M | – | 10.7 % |
| Other generic revenuesDriver not specified. | 3.98M | – | (7.8) % |
| Generics and Other total net revenuesGrowth reflected generic pharmaceutical products. | $108.4M | – | 9.9 % |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full Year 2026 outlook
- RevenueTotal Company: $1,085 million - $1,125 million; Cortrophin Gel: $480 million - $500 million; ILUVIEN: $80 million - $85 million
- Gross margintotal company adjusted non-GAAP gross margin between 60.3% and 61.0%
- Tax rateannual U.S. GAAP effective tax rate between 27% and 29%; tax rate of 26% for computation of adjusted non-GAAP diluted earnings per share
- NoteAdjusted Non-GAAP EBITDA: $290 million - $300 million
- NoteAdjusted Non-GAAP Diluted EPS: $9.37 - $9.71
- Noteapproximately 21.5 million and 21.8 million shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPS
Capital returns
- Effective on May 8, 2026, ANI’s board of directors authorized a share repurchase program to repurchase up to $100.0 million of the Company’s common stock.
- During the third quarter of 2026, the Company repurchased 102,492 shares for approximately $7.5 million.
- From October 1 through November 2, 2026, ANI repurchased an additional 173,143 shares for approximately $12.5 million.
- Through November 2, 2026, ANI repurchased 275,635 shares under the share repurchase program for approximately $20.0 million.
What drove it
- Cortrophin Gel growth was driven by momentum from the gout expansion and continued progress in Nephrology, Neurology, Rheumatology, Ophthalmology, and Pulmonology.
- New gout patient cases doubled quarter-over-quarter and the number of new prescribers increased approximately 67%.
- ILUVIEN growth reflected increased volumes and phasing of international shipments.
- Generic pharmaceutical products benefited from strong market demand for existing products and new product launches in 2025 and 2026.
- Gross-margin expansion was primarily due to a favorable product-mix shift and revenue recognized under the Harmony Agreement, tempered by increased sales of products that bear a royalty payable.
- The company launched 16 new Generics products year-to-date.
Concerns
- Revenue conversion was slower than expected in both existing specialties and gout because of capacity constraints in the specialty pharmacy network.
- Brands net revenues decreased 6.5% compared with the same period in 2025, reflecting a net decrease in demand for certain products.
- Cortrophin Gel full-year revenue guidance was revised to $480 million - $500 million from $520 million - $540 million.
- The Egetis offer remains subject to customary closing conditions, including acceptance by shareholders representing at least 90 percent of outstanding shares and necessary regulatory approvals.
- The Egetis offer is financed through cash on hand and new debt financing provided by JPMorgan Chase Bank, N.A.
What to watch
- Expansion of the specialty pharmacy network and patient-support capabilities intended to accelerate demand conversion for Cortrophin Gel.
- Execution toward approximately 40% year-over-year growth in 2026 for Cortrophin.
- Performance against revised Cortrophin Gel revenue guidance of $480 million - $500 million.
- Progress of the proposed Egetis acquisition, for which the acceptance period is expected to commence on or around November 20, 2026 and expire on or around December 18, 2026.
- Further capital deployment under the remaining portion of the $100.0 million share repurchase authorization.
Balance sheet and cash flow
- As of September 30, 2026, unrestricted cash and cash equivalents were $420.8 million.
- As of September 30, 2026, net accounts receivable were $304.5 million.
- As of September 30, 2026, principal value of outstanding debt was $616.9 million, inclusive of the Company’s senior convertible notes.
- Cash flow from operations was $198.8 million on a year to date basis.
- September 30, 2026 cash and cash equivalents were $ 420,758, compared with $ 285,585 at December 31, 2025.
- September 30, 2026 total assets were $ 1,567,661 and total liabilities were $ 930,548.
- September 30, 2026 debt, net was $ 274,314 and convertible notes, net were $ 309,556.
Analysis
ANI reported third-quarter net revenues of $290.8 million, up 27.6% year over year, led by Rare Disease. Cortrophin Gel revenue was $138.7 million, up 36.1%, while ILUVIEN revenue was $22.3 million, up 34.1%. Generics revenue of $104.5 million increased 10.7%, supported by existing-product demand and new launches. Brand royalties and other revenue added $11.5 million, including $2.0 million of development milestones and approximately $9.5 million of Harmony Agreement royalties.
Profitability improved with mix. GAAP gross margin rose to 61.6% from 59.0%, and non-GAAP gross margin rose to 61.8% from 59.2%. ANI attributed both increases primarily to favorable product mix and Harmony Agreement revenue, partly offset by more sales of products that bear a royalty payable. GAAP operating income was $52.4 million, GAAP net income available to common shareholders was $35.1 million, and diluted GAAP income per share was $1.51. Adjusted non-GAAP EBITDA increased 39.8% to $83.3 million, while adjusted non-GAAP diluted EPS was $2.70.
The key operating constraint is Cortrophin Gel conversion. ANI said demand indicators in gout remained strong, with new patient cases doubling quarter over quarter and new prescribers up approximately 67%, but conversion was slower than expected in gout and existing specialties because of specialty-pharmacy network capacity constraints. The company is expanding that network and patient-support capabilities. It simultaneously reduced the Cortrophin Gel full-year revenue range to $480 million - $500 million from $520 million - $540 million, despite describing a target of approximately 40% year-over-year Cortrophin growth in 2026.
Full-year total company revenue guidance was narrowed to $1,085 million - $1,125 million from $1,080 million - $1,140 million. ILUVIEN revenue guidance was revised to $80 million - $85 million from $78 million - $83 million. ANI raised adjusted non-GAAP EBITDA guidance to $290 million - $300 million from $285 million - $300 million and adjusted non-GAAP diluted EPS guidance to $9.37 - $9.71 from $9.19 - $9.69. The guidance framework also calls for total company adjusted non-GAAP gross margin of 60.3% to 61.0%.
Capital allocation included approximately $20.0 million of share repurchases through November 2 under the $100.0 million authorization. At September 30, ANI reported $420.8 million of unrestricted cash and cash equivalents, $616.9 million of principal value of outstanding debt, and $198.8 million of year-to-date cash flow from operations. The company also announced an offer to acquire Egetis for SEK 11.25 per share, with the offer value including outstanding incentive programs stated as approximately SEK 5.6 billion or approximately $560 million. The proposed transaction adds execution, financing, regulatory, and acceptance-condition milestones to monitor.
Management, verbatim
In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company.
Nikhil Lalwani, President and CEO of ANI
Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform.
Nikhil Lalwani, President and CEO of ANI
As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing.
Nikhil Lalwani, President and CEO of ANI
Not in the filing
stated, not guessed- Quarterly operating cash flow was not reported.
- Free cash flow was not reported.
- Dividend declaration or payment was not reported.
- Prior-quarter comparative figures were not reported for the reported financial metrics.
- A full-year 2026 GAAP net income, GAAP EPS, and GAAP operating income outlook was not reported.
- Prior-release outlook was not provided as a separate document; therefore, no actual-versus-prior-guidance comparison is presented.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
ANI Pharmaceuticals reported Q3 2026 financials, highlighted growth in its Cortrophin Gel and generics businesses, and disclosed a strategic acquisition of Egetis Therapeutics.
Ticker impact
ANI Pharmaceuticals filed an 8‑K reporting Q3 2026 results, narrowed 2026 revenue guidance to $1.085‑$1.125 B and announced an offer to acquire Egetis Therapeutics.
likely upward pressure as the market prices in updated EBITDA guidance and the acquisition premium.
The earnings beat, updated guidance and a 27% acquisition premium provide fresh, material information that can move the stock immediately.
Market effects
Strengthens the rare‑disease biotech sector as ANI expands its pipeline through the Egetis deal.
May boost investor sentiment toward US‑listed specialty pharma stocks.
The acquisition adds a rare‑disease therapy with orphan‑drug exclusivity, potentially influencing global rare‑disease treatment markets.
Counterpoint
The acquisition could dilute ANI's balance sheet and integration risk may offset short‑term upside.
Key entities
- companyANI Pharmaceuticals Inc.
US‑listed biotech reporting Q3 results and acquisition offer.
- companyEgetis Therapeutics AB
Swedish rare‑disease developer targeted for acquisition.
